bioAffinity Technologies (BIAF) Accumulated Expenses (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Accumulated Expenses data on file, last reported at $2.0 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.0 million, up 118.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 118.18% YoY), and the FY2025 annual result was $1.7 million, up 59.1% from the prior year.
• Accumulated Expenses improved to $2.0 million in Q1 2026 per BIAF's latest filing, from $1.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.0 million in Q1 2026 and troughed at $281085.0 in Q1 2023.
• A 5-year average of $1.0 million and a median of $969093.0 in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses sank 59.76% in 2023, then soared 214.25% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $541894.0 in 2022, then surged by 112.18% to $1.1 million in 2023, then dropped by 6.09% to $1.1 million in 2024, then soared by 59.1% to $1.7 million in 2025, then increased by 18.39% to $2.0 million in 2026.
• Business Quant data shows BIAF's Accumulated Expenses at $2.0 million in Q1 2026, $1.7 million in Q4 2025, and $984547.0 in Q3 2025.